ArticleJAC-antimicrobial resistance2025
Insufficient cerebrospinal fluid penetration of tedizolid: a case report.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing Tedizolid Dosing in Cerebral Nocardiosis: Clinical Impact of Direct Unbound Concentration Measurement and Population PK Modelling in Two Cases.JAC-antimicrobial resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Tedizolid, a novel oxazolidinone developed for the treatment of skin and soft tissue infections, exhibits a longer half-life than linezolid, with reduced myelosuppression and neurotoxicity. However, its penetration into the cerebrospinal fluid (CSF) remains poorly characterized. Our case report evaluated the CSF penetration of tedizolid. Case presentation: We present a case of parameningeal aseptic meningitis secondary to otogenic skull base osteomyelitis. Tedizolid concentrations in CSF and serum were measured using liquid chromatography and tandem mass spectrometry. The trough CSF concentration of tedizolid was below the limit of quantification, whereas the corresponding serum concentration was within the expected therapeutic range. A brief review of the literature corroborated the observation that CSF penetration of tedizolid was markedly lower than that of linezolid. Conclusion: Considering the consistently low CSF concentrations of tedizolid, linezolid remains the preferred agent for the treatment of CNS infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.